Therapeutics case studies
How we maximise the value of our clients' development approach while reducing costs and timelines
Learn more on how we bring life changing therapies to market.
Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.
Patient support services
A sponsor needed to recruit nearly 500 patients for a pivotal study in an ultra rare disease. The study's demanding protocol posed significant difficulties for patients. ICON was able to revise the protocol, reducing patient burden, and implemented a global recruitment strategy and additional support that allowed recruitment to be completed ahead of schedule, saving the sponsor an estimated $700,000.
Virtual development model
A venture-backed biopharmaceutical company focused on therapies for rare diseases needed to accelerate late-stage development and commercialization. ICON provided technical and commercial assessments, collaborating closely to simplify the development program and develop ePROs and a novel biomarker approach for the rare disease asset.
Transforming a partnership into a blended model
A 10-year existing FSO partnership was expanded to incorporate a blended model to aid sourcing niche roles across multiple geographies whilst the sponsor maintained greater control of key areas.
Cardiovascular safety in a rare disease study
A biotech company sought ICON's help to analyse and report on a limited data set to demonstrate cardiovascular safety in a rare disease study.
Partnership model evolutions for Top 10 pharma partner
A customised blended model has benefitted a top 10 pharma partner as their organisation has evolved over 13 years.
.jpg?crop=yes&w=2048&h=1077&a=0,145&itok=RDTz0ZT8 "Accellacare clinical research models"){kind=icon}
In-Home Services: Accelerated patient recruitment
A large pharma company was attempting to recruit 50 patients, including 15 treatment-naive patients, in a global study for a rare pulmonary disorder.